Article
Dapagliflozin improves early diabetic nephropathy by downregulating PPP2R2A and CXCL12/S100A13 through ROS- dependent
2022-05-10
Abstract excerpt
Diabetic nephropathy (DN) is a common chronic complication of diabetes mellitus (DM), and dapagliflozin, a representative drug of sodium-glucose co-transport protein 2 inhibitors (SGLT2i), is a novel hypoglycemic agent for the treatment of type 2 diabetes mellitus (T2DM), which has been shown to reverse microalbuminuria in early type 2 diabetic nephropathy (T2DN), but the mechanism of action remains to be elucidat...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- ed8c4365-6d14-5337-b51d-a7eba375296b
- DOI
- 10.21203/rs.3.rs-1511213/v1
